In the world of regenerative medicine, platelet-rich plasma (PRP) and platelet lysate (PL) are two biologic tools gaining traction in the treatment of orthopedic injuries, arthritis, chronic pain, and more. But before diving into their differences, let’s ask a more fundamental question that’s sparking scientific debate:
Are platelets even cells? Or are they just fragments of something bigger?
This seemingly philosophical question has real implications for how we harness platelets therapeutically. Understanding the biology of these unique blood components helps clarify why PRP and platelet lysate act so differently, and how physicians can choose the right tool for the right tissue.
What Are Platelets, Really?
Platelets are often called “small blood cells,” but they’re more accurately described as anucleate fragments of megakaryocytes, large cells in the bone marrow that release thousands of platelets into circulation.
- They lack a nucleus (and therefore can’t divide).
- They contain organelles like mitochondria, alpha-granules, lysosomes, and a robust cytoskeletal network.
- They’re metabolically active, capable of protein synthesis using pre-formed mRNAs.
- They play central roles in hemostasis, immune signaling, inflammation, and tissue repair.
So, are they cells or fragments?
According to a 2025 review in Circulation Research, platelets might occupy a middle ground: “not conventional cells,” but not mere debris either. Some experts even propose that platelets are evolutionarily advanced versions of extracellular vesicles.
“Platelets lack genomic DNA but carry RNA and organelles, perform functions independently, and respond to environmental signals — all hallmarks of cellular life, minus a nucleus.” — Boilard et al., 2025
Inside the Platelet: More Than Just a Clotting Agent
Platelets are biological powerhouses. Their dense and alpha-granules contain:
- Growth factors: PDGF, TGF-β, VEGF, EGF, IGF, b-FGF
- Cytokines and chemokines: IL-1, PF4, RANTES
- Enzymes: MMPs for tissue remodeling
- Neurotrophic molecules: BDNF, serotonin, dopamine
Upon activation, platelets release these factors either directly or via extracellular vesicles, making them key orchestrators of wound healing and regeneration.
PRP vs. Platelet Lysate: What’s the Difference?
Both PRP and platelet lysate are derived from platelets, yet they differ significantly in structure, composition, and clinical effect. Platelet-Rich Plasma (PRP) is a concentrated plasma containing intact platelets. It’s prepared by centrifuging whole blood to isolate platelets, which are then injected into the target area. Once administered, PRP gradually releases growth factors over time as the platelets degranulate, providing a sustained healing response. PRP typically has a short shelf life and is prepared fresh for each patient, making it ideal for tendon, joint, and ligament injections where prolonged repair is desired.
Platelet Lysate (PL), on the other hand, is a cell-free fluid created by lysing platelets through methods like freeze-thaw cycles or sonication and removing cellular debris. This process releases all growth factors instantly, resulting in a powerful biologic solution ready for immediate action. Unlike PRP, platelet lysate can be standardized, frozen, and stored for later use. It’s often used in cell culture or in clinical applications where a rapid biologic response or minimal immune stimulation is preferred.
In essence, PRP is like delivering “growth factor bombs” that release slowly at the site of injury, while platelet lysate is like pouring out the potent liquid center, all the active ingredients without the surrounding membrane. Think of PRP as having a “hard candy shell” that dissolves over time, whereas platelet lysate strips away that shell to deliver the full biologic payload instantly.
Which One Should You Use?
Choose PRP when:
- You want a gradual, sustained release of healing signals
- You’re treating tendinopathy or mild arthritis
- You need the physical scaffold of platelets at the site of injection
Choose Platelet Lysate when:
- You need the immediate availability of bioactive factors
- You’re working with cell culture or ex vivo expansion (e.g., mesenchymal stem cells)
- You need a standardized, cell-free product that avoids immunogenic debris
As emphasized by the American Medical Society for Sports Medicine (AMSSM), both products have merit but should be used responsibly and ethically within current regulatory frameworks.
Future Directions: Beyond the Nucleus
Research is increasingly exploring:
- Allogeneic platelet lysates from screened donors for off-the-shelf use
- Platelet-derived extracellular vesicles (p-EVs) as drug delivery tools
- Combining PL with biomaterials or scaffolds for precision regenerative therapy
As our understanding of platelet biology evolves, so does our ability to harness their power more precisely and safely.
Final Thoughts
Whether you call them cells, fragments, or evolution’s clever workaround, platelets are uniquely equipped for healing. Their versatility is precisely why they’re so effective, and why differentiating between PRP and platelet lysate isn’t just academic. It’s the difference between slow infusion and immediate delivery, between cell-based and cell-free, and ultimately, between biologic potential and precision medicine.
References
Finnoff JT, Awan TM, Borg-Stein J, et al.
Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine. 2021;
31(6):530-541. doi:10.1097/JSM.0000000000000973.
Sheean AJ, Anz AW, Bradley JP.
Arthroscopy : The Journal of Arthroscopic & Related Surgery : Official Publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2021;37(9):2732-2734. doi:10.1016/j.arthro.2021.07.003.
Zamani M, Yaghoubi Y, Movassaghpour A, et al.
Journal of Cellular Physiology. 2019;234(10):17172-17186. doi:10.1002/jcp.28496.
Burnouf T, Chou ML, Lundy DJ, et al.
Journal of Biomedical Science. 2023;30(1):79. doi:10.1186/s12929-023-00972-w.
Leading Journal
Burnouf T, Strunk D, Koh MB, Schallmoser K.
Biomaterials. 2016;76:371-87. doi:10.1016/j.biomaterials
.2015.10.065.
Leading Journal
Sovkova V, Vocetkova K, Hedvičáková V, et al.
International Journal of Molecular Sciences. 2021;22(9):4539. doi:10.3390/ijms22094539.
Henschler R, Gabriel C, Schallmoser K, Burnouf T, Koh MBC.
Transfusion. 2019;59(4):1407-1413. doi:10.1111/trf.15174.
Delila L, Wu YW, Nebie O, et al.
Platelets. 2021;
32(2):259-272. doi:10.1080/09537104.2020.1849603.
Klatte-Schulz F, Schmidt T, Uckert M, et al.
International Journal of Molecular Sciences. 2018;19(1):E212. doi:10.3390/ijms19010212.
Acebes-Huerta A, Martínez-Botía P, Carbajo-Argüelles G, et al.
Acta Biomaterialia. 2024;177:132-147. doi:10.1016/j.actbio.2024.01.029.
Leading Journal
Boilard E, Burger D, Buzas E, et al.
Circulation Research. 2025;
136(4):442-452. doi:10.1161/CIRCRESAHA.124.324721.
Leading Journal New Research
Tilburg J, Becker IC, Italiano JE.
Blood. 2022;139(22):3245-3254. doi:10.1182/blood.2020009302.
Leading Journal
Puricelli C, Boggio E, Gigliotti CL, et al.
International Journal of Molecular Sciences. 2023;24(5):4565. doi:10.3390/ijms24054565.
Li L, Ni R, Li Z, et al.
Frontiers in Bioscience (Landmark Edition). 2022;27(11):313. doi:10.31083/j.fbl2711313.